Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $505,120.70 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 15,485 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $32.62, for a total value of $505,120.70. Following the transaction, the insider now owns 74,158 shares in the company, valued at approximately $2,419,033.96. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Catriona Yale also recently made the following trade(s):

• On Wednesday, October 30th, Catriona Yale sold 4,515 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.53, for a total value of $146,872.95.
• On Monday, October 14th, Catriona Yale sold 6,136 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.03, for a total value of $184,264.08.
• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.65, for a total value of $152,075.00.
• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total value of $106,684.76.
• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.52, for a total value of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.53, for a total value of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $143,052.00.

Akero Therapeutics Trading Up 4.9 %

Shares of AKRO stock opened at $32.33 on Monday. The stock’s fifty day moving average price is $28.32 and its two-hundred day moving average price is $24.81. The company has a market cap of $2.24 billion, a PE ratio of -9.48 and a beta of -0.26. Akero Therapeutics, Inc. has a fifty-two week low of $12.96 and a fifty-two week high of $37.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. Equities analysts predict that Akero Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

Large investors have recently modified their holdings of the business. Principal Financial Group Inc. boosted its holdings in shares of Akero Therapeutics by 15.6% during the 1st quarter. Principal Financial Group Inc. now owns 13,766 shares of the company’s stock valued at $348,000 after acquiring an additional 1,858 shares in the last quarter. Capstone Investment Advisors LLC acquired a new stake in shares of Akero Therapeutics during the 1st quarter valued at $2,205,000. Swiss National Bank boosted its holdings in shares of Akero Therapeutics by 19.9% during the 1st quarter. Swiss National Bank now owns 105,000 shares of the company’s stock valued at $2,652,000 after acquiring an additional 17,400 shares in the last quarter. Headlands Technologies LLC boosted its holdings in shares of Akero Therapeutics by 253.5% during the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock valued at $107,000 after acquiring an additional 3,024 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Akero Therapeutics by 2,366.0% during the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after acquiring an additional 1,183 shares in the last quarter.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research report on Tuesday, September 17th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $43.20.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.